Top Research Reports for Novo Nordisk, Tesla & Airbnb
https://www.zacks.com/commentary/2239296/top-research-reports-for-novo-nordisk-tesla-airbnb?cid=CS-ZC-FT-research_daily-2239296
Mar 12, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Tesla, Inc. (TSLA) and Airbnb, Inc. (ABNB).
0
All You Need to Know About Novo Nordisk (NVO) Rating Upgrade to Buy
https://www.zacks.com/stock/news/2239424/all-you-need-to-know-about-novo-nordisk-nvo-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2239424
Mar 12, 2024 - Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?
https://www.zacks.com/stock/news/2239193/novo-nordisk-nvo-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2239193
Mar 12, 2024 - Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322
Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
0
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238077
Mar 08, 2024 - Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
0
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
https://www.fool.com/investing/2024/03/05/a-new-competitor-to-wegovy-could-be-on-the-way-sho/?source=iedfolrf0000001
Mar 05, 2024 - Here's why I'm not worried.
0
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
https://www.zacks.com/stock/news/2235993/new-to-investing-this-1-medical-stock-could-be-the-perfect-starting-point?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_focus_list-2235993
Mar 05, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
0
2 No-Brainer Biotech Stocks to Buy Right Now
https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 21, 2024 - These stocks are used to beating the market.
0
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
https://www.fool.com/investing/2024/02/18/novo-nordisk-has-more-than-ozempic-one-of-its/?source=iedfolrf0000001
Feb 18, 2024 - It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too.
0
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
https://www.zacks.com/stock/news/2224747/why-novo-nordisk-nvo-is-a-top-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_focus_list-2224747
Feb 12, 2024 - The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
0